Methylated Septin9 has moderate diagnostic value in colorectal cancer detection in Chinese population: a multicenter study

Lu, Dongcheng; Zhang, Qifang; Li, Li; Luo, Xin; Liang, Bin; Lu, Yihan; Hu, Bang-li; Jiang, Haixing

doi:10.1186/s12876-022-02313-x

Cited by 11 publications

(8 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 7212 publications were queried based on our search strategy at first, and 79 eligible articles published from 2008 to 2022 were incorporated into our meta-analysis after examination of the abstract and comprehension of the full text ( Table S1 ). All included studies consisted of quantitative analysis of ctDNA concentration ( n = 11) [ 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 ] and qualitative analysis of tumor-specific gene methylation in ctDNA ( n = 67) [ 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , ...…”

Section: Resultsmentioning

confidence: 99%

“…All included studies consisted of quantitative analysis of ctDNA concentration ( n = 11) [ 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 ] and qualitative analysis of tumor-specific gene methylation in ctDNA ( n = 67) [ 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 ,…”

Section: Resultsmentioning

confidence: 99%

“…concentration (n = 11) [40][41][42][43][44][45][46][47][48][49][50] and qualitative analysis of tumor-specific gene methylation in ctDNA (n = 67) as well as both quantitative and qualitative analysis (n = 1 [119]. Among these publications, 34 articles [51,59,60,[62][63][64][65][66][67][68][70][71][72]74,75,78,79,[81][82][83]90,91,96,[100][101][102]104,105,107,108,110,112,115,116] evaluated the diagnostic efficiency o septin9 (SEPT9) methylation for CRC. In our meta-analysis, a total population of 8076 CRC patients and 17164 control sub jects were included.…”

Section: Studies Characteristicsmentioning

confidence: 99%

See 2 more Smart Citations

Using Circulating Tumor DNA as a Novel Biomarker to Screen and Diagnose Colorectal Cancer: A Meta-Analysis

Liang

Chen

et al. 2023

JCM

View full text Add to dashboard Cite

(1) Background: Circulating tumor DNA (ctDNA) has emerged as a promising biomarker for many kinds of tumors. However, whether ctDNA could be an accurate diagnostic biomarker in colorectal cancer (CRC) remains to be clarified. The aim of this study was to evaluate the diagnostic accuracy of ctDNA in CRC. (2) Methods: PubMed, Web of Science, and Cochrane databases were searched to identify studies reporting the use of ctDNA to screen and diagnose CRC, and all relevant studies published until October 2022 were enrolled for our analysis. These studies were divided into three primer subgroups: the subgroup of quantitative or qualitative analysis of ctDNA and the subgroup of septin9 (SEPT9) methylation assay. (3) Results: A total of 79 qualified articles with 25,240 subjects were incorporated into our meta-analysis. For quantitative studies, the combined sensitivity (SEN), specificity (SPE), and diagnostic odds ratio (DOR) were 0.723 (95% CI: 0.623–0.803), 0.920 (95% CI: 0.827–0.966), and 23.305 (95% CI: 9.378–57.906), respectively, yielding an AUC of 0.860. The corresponding values for qualitative studies were 0.610 (95% CI: 0.566–0.651), 0.891 (95% CI: 0.878–0.909), 12.569 (95% CI: 9.969–15.848), and 0.823, respectively. Detection of SEPT9 methylation depicted an AUC of 0.879, with an SEN of 0.679 (95% CI: 0.622–0.732), an SPE of 0.903 (95% CI: 0.878–0.923), and a DOR of 20.121 (95% CI:14.404–28.106), respectively. (4) Conclusion: Blood-based ctDNA assay would be a potential novel biomarker for CRC screening and diagnosis. Specifically, quantitative analysis of ctDNA or qualitative analysis of SEPT9 methylation exhibited satisfying diagnostic efficiency. Larger sample studies are needed to further confirm our conclusions and to make the ctDNA approach more sensitive and specific.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Studies Characteristicsmentioning

confidence: 99%

See 1 more Smart Citation

Using Circulating Tumor DNA as a Novel Biomarker to Screen and Diagnose Colorectal Cancer: A Meta-Analysis

Liang

Chen

et al. 2023

JCM

View full text Add to dashboard Cite

show abstract

“…In the USA, age-standardized mortality and incidence rates of CRC have recently significantly decreased[ 2 ]. Several screening tests, including colonoscopy and the fecal occult blood test (FOBT), are currently used in CRC detection[ 3 ]. In addition, tumor markers such as alpha-fetoprotein (AFP), carbohydrate antigen 199 (CA199) and carcinoembryonic antigen (CEA) are common indices used in the diagnosis of CRC[ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Diagnostic accuracy of the multi-target stool DNA test in detecting colorectal cancer: A hospital-based study

Gao¹,

Lv²,

Zhao³

et al. 2023

World J Gastrointest Oncol

View full text Add to dashboard Cite

BACKGROUND The multi-target stool DNA test (MT-sDNA) has potential utility in the detection of colorectal cancer (CRC), but validation of its clinical accuracy has been limited in China. AIM To evaluate the diagnostic performance of MT-sDNA and investigate the combined diagnostic value of alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), and carbohydrate antigen 199 (CA199) with MT-sDNA in CRC and adenomas. METHODS We evaluated the performance of the MT-sDNA kit based on a hospital clinical trial. In this case-control study, 135 participants from the Affiliated Hospital of Medical School of Ningbo University, including 51 CRC patients, 23 patients with adenomas, and 61 healthy controls were enrolled. We used a risk scoring system to determine the positivity of tests with histological diagnosis or colonoscopy as the reference standard. RESULTS The main indices of sensitivity, specificity and accuracy were evaluated. The sensitivity and specificity for CRC detection were 90.2% and 83.3%, respectively, with an accuracy of 89.8%. For adenoma, the sensitivity and specificity were 56.5% and 68.9%, respectively, with an accuracy of 73.1%. The sensitivity and specificity of MT-sDNA combined with CEA in the diagnosis of adenoma were 78.3% and 60.7%, respectively. CONCLUSION The MT-sDNA test showed better performance in the detection of CRC, which was superior to AFP, CEA, and CA199 separately, but not for predicting adenomas. The combination of MT-sDNA with CEA further improved the sensitivity for adenoma diagnosis.

show abstract

“…Compared with blood or stool, urine represents a better source because of its simple collection method, high patient acceptance and ability to collect repeated samples. Many urine biomarkers for CRC have been studied and have demonstrated potential diagnostic value[ 7 - 9 ]. Matrix metalloproteinases (MMPs), as a group of zinc-dependent endopeptidases, participate in the degradation of the extracellular matrix and are secreted and activated outside the cell.…”

Section: Introductionmentioning

confidence: 99%

Diagnostic value of matrix metalloproteinases 2, 7 and 9 in urine for early detection of colorectal cancer

Zhang¹,

Zhang²,

Jiang³

et al. 2023

World J Gastrointest Surg

View full text Add to dashboard Cite

BACKGROUND A noninvasive biomarker with high diagnostic performance is urgently needed for the early diagnosis of colorectal cancer (CRC). AIM To evaluate the diagnostic value of matrix metalloproteinases (MMPs) 2, 7 and 9 in urine for CRC. METHODS Of 59 healthy controls, 47 patients with colon polyps and 82 patients with CRC were included in this study. Carcinoembryonic antigen (CEA) in serum and MMP2, MMP7, and MMP9 in urine were detected. The combined diagnostic model of the indicators was established by binary logistic regression. The receiver operating characteristic curve (ROC) of the subjects was used to evaluate the independent and combined diagnostic value of the indicators. RESULTS The MMP2, MMP7, MMP9, and CEA levels in the CRC group differed significantly from levels in the healthy controls ( P < 0.05). The levels of MMP7, MMP9, and CEA also differed significantly between the CRC group and the colon polyps group ( P < 0.05). The area under the curve (AUC) distinguishing between the healthy control and the CRC patients using the joint model with CEA, MMP2, MMP7 and MMP9 was 0.977, and the sensitivity and specificity were 95.10% and 91.50%, respectively. For early-stage CRC, the AUC was 0.975, and the sensitivity and specificity were 94.30% and 98.30%, respectively. For advanced stage CRC, the AUC was 0.979, and the sensitivity and specificity were 95.70% and 91.50%, respectively. Using CEA, MMP7 and MMP9 to jointly established a model distinguishing the colorectal polyp group from the CRC group, the AUC was 0.849, and the sensitivity and specificity were 84.10% and 70.20%, respectively. For early-stage CRC, the AUC was 0.818, and the sensitivity and specificity were 76.30% and 72.30%, respectively. For advanced stage CRC, the AUC was 0.875, and the sensitivity and specificity were 81.80% and 72.30%, respectively. CONCLUSION MMP2, MMP7 and MMP 9 may exhibit diagnostic value for the early detection of CRC and may serve as auxiliary diagnostic markers for CRC.

show abstract

Methylated Septin9 has moderate diagnostic value in colorectal cancer detection in Chinese population: a multicenter study

Cited by 11 publications

References 35 publications

Using Circulating Tumor DNA as a Novel Biomarker to Screen and Diagnose Colorectal Cancer: A Meta-Analysis

Using Circulating Tumor DNA as a Novel Biomarker to Screen and Diagnose Colorectal Cancer: A Meta-Analysis

Diagnostic accuracy of the multi-target stool DNA test in detecting colorectal cancer: A hospital-based study

Diagnostic value of matrix metalloproteinases 2, 7 and 9 in urine for early detection of colorectal cancer

Contact Info

Product

Resources

About